Compositions and methods for treating cancers
OwnerElias Quijano, Peter Glazer +4inventors
InventorsElias Quijano, Peter Glazer, Bruce C. Turner, Dale Ludwig, Venugopalareddy Bommireddyvenkata, Luisa Escobar-Hoyos
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for treating cancer by administering a complex formed between a therapeutic polynucleotide and a 3E10 antibody or variant thereof, or antigen-binding fragment thereof. In some instances, the complexes are stabilized through a molar ratio of 3E10 antibody or variant thereof, or antigen-binding fragment thereof to therapeutic polynucleotide of at least about 2:1.
Claims30
A method for treating a cancer of the central nervous system in a subject in need thereof, the method comprising:
- parenterally administering to the periphery of the subject a therapeutically effective amount of a composition comprising a complex formed between (i) a therapeutic polynucleotide, and (ii) a 3E10 antibody or variant thereof, or antigen-binding fragment thereof,
- wherein the 3E10 antibody or antigen-binding fragment thereof comprises:
- (a) a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of 3E10-VL-CDR1m,
- (b) a VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2m,
- (c) a VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3m,
- (d) a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of 3E10-VH-CDR 1m,
- (e) a VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR2m, and
- (f) a VH CDR3 comprising the amino acid sequence of 3E10-VH-CDR3m.
-30. (canceled)
(canceled)
-42. (canceled)
-54. (canceled)
-63. (canceled)
(canceled)
-68. (canceled)
(canceled)
(canceled)
-255. (canceled)
A pharmaceutical composition comprising a complex formed between (i) a therapeutic polynucleotide, and (ii) a 3E10 antibody or variant thereof, or antigen-binding fragment thereof wherein the 3E10 antibody or antigen-binding fragment thereof comprises:
- (a) a light chain variable region (VL) complementarity determining region (CDR) 1 comprising the amino acid sequence of 3E10-VL-CDR1m,
- (b) a VL CDR2 comprising the amino acid sequence of 3E10-VL-CDR2m,
- (c) a VL CDR3 comprising the amino acid sequence of 3E10-VL-CDR3m,
- (d) a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of 3E10-VH-CDR 1m,
- (e) a VH CDR2 comprising the amino acid sequence of 3E10-VH-CDR2m, and
- (f) a VH CDR3 comprising the amino acid sequence of 3E10-VH-CDR3m;
- and wherein
- (I) the composition is formulated for parenteral administration,
- (II) the composition is for treating a cancer of the central nervous system and the composition is formulated for parenteral administration to the periphery of the subject,
- (III) the composition is for treating a cancer of the central nervous system and the composition is formulated for injection into the central nervous system, or
- (IV) the composition is for treating melanoma and the composition is formulated for parenteral administration.
257-326. (canceled)
Dependencies are inferred from the claim text.